200 related articles for article (PubMed ID: 28707398)
41. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
42. Bortezomib-based induction improves progression-free survival of myeloma patients harboring 17p deletion and/or t(4;14) and overcomes their adverse prognosis.
El-Ghammaz AM; Abdelwahed E
Ann Hematol; 2016 Aug; 95(8):1315-21. PubMed ID: 27184486
[TBL] [Abstract][Full Text] [Related]
43. Is double autologous stem-cell transplantation appropriate for new multiple myeloma patients?
van Rhee F
Nat Clin Pract Oncol; 2008 Feb; 5(2):70-1. PubMed ID: 17984985
[No Abstract] [Full Text] [Related]
44. 10 years of experience with thalidomide in multiple myeloma patients: report of the Czech Myeloma Group.
Minarik J; Sandecka V; Maisnar V; Gregora E; Spicka I; Starostka D; Plonkova H; Jarkovsky J; Walterova L; Wrobel M; Adamova D; Pika T; Melicharova H; Pour L; Radocha J; Pavlicek P; Straub J; Gumulec J; Bacovsky J; Adam Z; Scudla V; Hajek R
Leuk Res; 2013 Sep; 37(9):1063-9. PubMed ID: 23845888
[TBL] [Abstract][Full Text] [Related]
45. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
[TBL] [Abstract][Full Text] [Related]
46. [Response rates to first-line treatment in eligible patients to autologous stem transplantation in Chile].
Peña C; Rojas-Vallejos J; Espinoza M; Donoso J; Soto P; Cardemil D; Aranda S; Contreras C; Vergara CG; LA Rocca G; Osorio R; López-Vidal H; Chandía M; Rojas C
Rev Med Chil; 2019 Dec; 147(12):1561-1568. PubMed ID: 32186620
[TBL] [Abstract][Full Text] [Related]
47. Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation.
Brioli A; Perrone G; Patriarca F; Pezzi A; Nobile F; Ballerini F; Motta MR; Ronconi S; Tacchetti P; Catalano L; Zannetti BA; Rizzi S; Volpe S; Zamagni E; Liberati AM; Mancuso K; Boccadoro M; Davies FE; Morgan GJ; Palumbo A; Cavo M
Bone Marrow Transplant; 2015 May; 50(5):673-8. PubMed ID: 25642764
[TBL] [Abstract][Full Text] [Related]
48. Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management.
Rajkumar SV
Am J Hematol; 2013 Mar; 88(3):226-35. PubMed ID: 23440663
[TBL] [Abstract][Full Text] [Related]
49. Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma.
Ludwig H; Viterbo L; Greil R; Masszi T; Spicka I; Shpilberg O; Hajek R; Dmoszynska A; Paiva B; Vidriales MB; Esteves G; Stoppa AM; Robinson D; Ricci D; Cakana A; Enny C; Feng H; van de Velde H; Harousseau JL
J Clin Oncol; 2013 Jan; 31(2):247-55. PubMed ID: 23091109
[TBL] [Abstract][Full Text] [Related]
50. [Treatment of transplant-eligible symptomatic multiple myeloma].
Nakaseko C
Rinsho Ketsueki; 2014 Oct; 55(10):2016-26. PubMed ID: 25297767
[No Abstract] [Full Text] [Related]
51. Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma.
Cavo M; Di Raimondo F; Zamagni E; Patriarca F; Tacchetti P; Casulli AF; Volpe S; Perrone G; Ledda A; Ceccolini M; Califano C; Bigazzi C; Offidani M; Stefani P; Ballerini F; Fiacchini M; de Vivo A; Brioli A; Tosi P; Baccarani M
J Clin Oncol; 2009 Oct; 27(30):5001-7. PubMed ID: 19720903
[TBL] [Abstract][Full Text] [Related]
52. Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens.
Niesvizky R; Flinn IW; Rifkin R; Gabrail N; Charu V; Clowney B; Essell J; Gaffar Y; Warr T; Neuwirth R; Zhu Y; Elliott J; Esseltine DL; Niculescu L; Reeves J
J Clin Oncol; 2015 Nov; 33(33):3921-9. PubMed ID: 26056177
[TBL] [Abstract][Full Text] [Related]
53. VEGF, VEGFR2 and GSTM1 polymorphisms in outcome of multiple myeloma patients treated with thalidomide-based regimens.
Lopes-Aguiar L; Delamain MT; Brito ABC; Lourenço GJ; Costa EFD; Oliveira GB; Vassallo J; De Souza CA; Lima CSP
Blood Cancer J; 2017 Jun; 7(6):e580. PubMed ID: 28665417
[No Abstract] [Full Text] [Related]
54. Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma.
Palumbo A; Avonto I; Bruno B; Ambrosini MT; Bringhen S; Cavallo F; Falco P; Boccadoro M
Eur J Haematol; 2006 Apr; 76(4):273-7. PubMed ID: 16519697
[TBL] [Abstract][Full Text] [Related]
55. Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma.
Zannetti BA; Tacchetti P; Pantani L; Gamberi B; Tosi P; Rocchi S; Cellini C; Ronconi S; Pezzi A; Mancuso K; Rizzello I; Caratozzolo I; Martello M; Dozza L; Cavo M; Zamagni E
Ann Hematol; 2017 Dec; 96(12):2071-2078. PubMed ID: 29063955
[TBL] [Abstract][Full Text] [Related]
56. Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression-free survival in multiple myeloma.
Maiolino A; Hungria VT; Garnica M; Oliveira-Duarte G; Oliveira LC; Mercante DR; Miranda EC; Quero AA; Peres AL; Barros JC; Tanaka P; Magalhães RP; Rego EM; Lorand-Metze I; Lima CS; Renault IZ; Braggio E; Chiattone C; Nucci M; de Souza CA;
Am J Hematol; 2012 Oct; 87(10):948-52. PubMed ID: 22730113
[TBL] [Abstract][Full Text] [Related]
57. Early response-based intensification of primary therapy in newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplantation: phase II study.
Ahn SY; Jung SH; Joo YD; Lee WS; Lee SM; Choi CW; Kim SJ; Kim K; Lee JJ;
Ann Hematol; 2014 Sep; 93(9):1571-7. PubMed ID: 24728664
[TBL] [Abstract][Full Text] [Related]
58. Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of a randomized comparison with vincristine, doxorubicin, and dexamethasone.
Mellqvist UH; Lenhoff S; Johnsen HE; Hjorth M; Holmberg E; Juliusson G; Tangen JM; Westin J;
Cancer; 2008 Jan; 112(1):129-35. PubMed ID: 17973267
[TBL] [Abstract][Full Text] [Related]
59. Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma.
Gertz MA; Lacy MQ; Inwards DJ; Chen MG; Pineda AA; Gastineau DA; Greipp PR; Lust JA; Tefferi A; Witzig TE; Kyle RA; Litzow MR
Bone Marrow Transplant; 1999 Feb; 23(3):221-6. PubMed ID: 10084252
[TBL] [Abstract][Full Text] [Related]
60. Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma.
Leleu X; Fouquet G; Hebraud B; Roussel M; Caillot D; Chrétien ML; Arnulf B; Szalat R; Garderet L; Benajiba L; Pegourie B; Regny C; Royer B; Caulier A; Stoppa AM; Garciaz S; Touzeau C; Chaleteix C; Fermand JP; Loiseau HA; Facon T; Attal M; Moreau P;
Leukemia; 2013 Nov; 27(11):2242-4. PubMed ID: 23558525
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
